Viruses seen by our cells: The role of viral RNA sensors

Journal of Immunology Research

Volumn 2018, Issue , 2018, Pages

  Said, Elias A ^a   Tremblay, Nicolas ^b   Al Balushi, Mohammed S ^a   Al Jabri, Ali A ^a   Lamarre, Daniel ^b  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; INTERFERON; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; LIGAND; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; RNA HELICASE; SMALL CYTOPLASMIC RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; VIRUS RNA; VIRUS VACCINE; AUTACOID;

ANTIVIRAL THERAPY; HUMAN; INNATE IMMUNITY; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; RNA VIRUS; TLR SIGNALING; VIRUS DETECTION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS PATHOGENESIS; ANIMAL; GENETICS; IMMUNOLOGY; METABOLISM; VIRUS;

ANIMALS; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTERFERON TYPE I; PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES; RNA HELICASES; RNA, VIRAL; TOLL-LIKE RECEPTORS; VIRUS DISEASES; VIRUSES;

EID: 85054764548     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2018/9480497     Document Type: Review

References (156)

1. L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature, vol. 413, no. 6857, pp. 732–738, 2001.
2. S. S. Diebold, M. Montoya, H. Unger et al., “Viral infection switches non-plasmacytoid dendritic cells into high interferon producers,” Nature, vol. 424, no. 6946, pp. 324–328, 2003.
3. M. Yoneyama, M. Kikuchi, T. Natsukawa et al., “The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses,” Nature Immunology, vol. 5, no. 7, pp. 730–737, 2004.
4. T. Saito, R. Hirai, Y. M. Loo et al., “Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 2, pp. 582–587, 2007.
5. B. Wu, A. Peisley, C. Richards et al., “Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5,” Cell, vol. 152, no. 1-2, pp. 276–289, 2013.
6. J. Liu, C. Qian, and X. Cao, “Post-translational modification control of innate immunity,” Immunity, vol. 45, no. 1, pp. 15–30, 2016.
7. Y. Zhou, C. He, L. Wang, and B. Ge, “Post-translational regulation of antiviral innate signaling,” European Journal of Immunology, vol. 47, no. 9, pp. 1414–1426, 2017.
8. N. P. Maharaj, E. Wies, A. Stoll, and M. U. Gack, “Conventional protein kinase C-α (PKC-α) and PKC-β negatively regulate RIG-I antiviral signal transduction,” Journal of Virology, vol. 86, no. 3, pp. 1358–1371, 2012.
9. E. Wies, M. K. Wang, N. P. Maharaj et al., “Dephosphorylation of the RNA sensors RIG-I and MDA5 by the phosphatase PP1 is essential for innate immune signaling,” Immunity, vol. 38, no. 3, pp. 437–449, 2013.
10. M. U. Gack, Y. C. Shin, C. H. Joo et al., “TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity,” Nature, vol. 446, no. 7138, pp. 916–920, 2007.
11. M. U. Gack, A. Kirchhofer, Y. C. Shin et al., “Roles of RIG-I N-terminal tandem CARD and splice variant in TRIM25-mediated antiviral signal transduction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 43, pp. 16743–16748, 2008.
12. R. Y. Sanchez David, C. Combredet, O. Sismeiro et al., “Comparative analysis of viral RNA signatures on different RIG-I-like receptors,” eLife, vol. 5, 2016.
13. H. Oshiumi, M. Miyashita, N. Inoue, M. Okabe, M. Matsumoto, and T. Seya, “The ubiquitin ligase Riplet is essential for RIG-I-dependent innate immune responses to RNA virus infection,” Cell Host & Microbe, vol. 8, no. 6, pp. 496–509, 2010.
14. H. Oshiumi, M. Matsumoto, S. Hatakeyama, and T. Seya, “Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-β induction during the early phase of viral infection,” The Journal of Biological Chemistry, vol. 284, no. 2, pp. 807–817, 2009.
15. J. Yan, Q. Li, A. P. Mao, M. M. Hu, and H. B. Shu, “TRIM4 modulates type I interferon induction and cellular antiviral response by targeting RIG-I for K63-linked ubiquitination,” Journal of Molecular Cell Biology, vol. 6, no. 2, pp. 154–163, 2014.
16. K. Kuniyoshi, O. Takeuchi, S. Pandey et al., “Pivotal role of RNA-binding E3 ubiquitin ligase MEX3C in RIG-I-mediated antiviral innate immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 15, pp. 5646–5651, 2014.
17. W. Zeng, L. Sun, X. Jiang et al., “Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity,” Cell, vol. 141, no. 2, pp. 315–330, 2010.
18. X. Jiang, L. N. Kinch, C. A. Brautigam et al., “Ubiquitin-induced oligomerization of the RNA sensors RIG-I and MDA5 activates antiviral innate immune response,” Immunity, vol. 36, no. 6, pp. 959–973, 2012.
19. C. S. Friedman, M. A. O’Donnell, D. Legarda-Addison et al., “The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response,” EMBO Reports, vol. 9, no. 9, pp. 930–936, 2008.
20. Y. Fan, R. Mao, Y. Yu et al., “USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase,” The Journal of Experimental Medicine, vol. 211, no. 2, pp. 313–328, 2014.
21. J. Cui, Y. Song, Y. Li et al., “USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors,” Cell Research, vol. 24, no. 4, pp. 400–416, 2014.
22. K. Arimoto, H. Takahashi, T. Hishiki, H. Konishi, T. Fujita, and K. Shimotohno, “Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7500–7505, 2007.
23. W. Wang, M. Jiang, S. Liu et al., “RNF122 suppresses antiviral type I interferon production by targeting RIG-I CARDs to mediate RIG-I degradation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 34, pp. 9581–9586, 2016.
24. J. Cui, L. Zhu, X. Xia et al., “NLRC5 negatively regulates the NF-κB and type I interferon signaling pathways,” Cell, vol. 141, no. 3, pp. 483–496, 2010.
25. C. B. Moore, D. T. Bergstralh, J. A. Duncan et al., “NLRX1 is a regulator of mitochondrial antiviral immunity,” Nature, vol. 451, no. 7178, pp. 573–577, 2008.
26. S. J. Choi, H. C. Lee, J. H. Kim et al., “HDAC6 regulates cellular viral RNA sensing by deacetylation of RIG-I,” The EMBO Journal, vol. 35, no. 4, pp. 429–442, 2016.
27. M. M. Hu, C. Y. Liao, Q. Yang, X. Q. Xie, and H. B. Shu, “Innate immunity to RNA virus is regulated by temporal and reversible sumoylation of RIG-I and MDA5,” The Journal of Experimental Medicine, vol. 214, no. 4, pp. 973–989, 2017.
28. Z. Mi, J. Fu, Y. Xiong, and H. Tang, “SUMOylation of RIG-I positively regulates the type I interferon signaling,” Protein & Cell, vol. 1, no. 3, pp. 275–283, 2010.
29. F. Hou, L. Sun, H. Zheng, B. Skaug, Q. X. Jiang, and Z. J. Chen, “MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response,” Cell, vol. 146, no. 3, pp. 448–461, 2011.
30. T. Kawai, K. Takahashi, S. Sato et al., “IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction,” Nature Immunology, vol. 6, no. 10, pp. 981–988, 2005.
31. E. Meylan, J. Curran, K. Hofmann et al., “Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus,” Nature, vol. 437, no. 7062, pp. 1167–1172, 2005.
32. R. B. Seth, L. Sun, C.-K. Ea, and Z. J. Chen, “Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3,” Cell, vol. 122, no. 5, pp. 669–682, 2005.
33. H. Xu, X. He, H. Zheng et al., “Structural basis for the prion-like MAVS filaments in antiviral innate immunity,” Biophysical Journal, vol. 106, no. 2, article 684a, 2014.
34. L.-G. Xu, Y.-Y. Wang, K.-J. Han, L.-Y. Li, Z. Zhai, and H.-B. Shu, “VISA is an adapter protein required for virus-triggered IFN-β signaling,” Molecular Cell, vol. 19, no. 6, pp. 727–740, 2005.
35. V. Hornung, J. Ellegast, S. Kim et al., “5′-Triphosphate RNA is the ligand for RIG-I,” Science, vol. 314, no. 5801, pp. 994–997, 2006.
36. A. Pichlmair, O. Schulz, C. P. Tan et al., “RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phos-phates,” Science, vol. 314, no. 5801, pp. 997–1001, 2006.
37. A. Baum, R. Sachidanandam, and A. Garcia-Sastre, “Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 37, pp. 16303–16308, 2010.
38. H. Kato, O. Takeuchi, E. Mikamo-Satoh et al., “Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5,” The Journal of Experimental Medicine, vol. 205, no. 7, pp. 1601–1610, 2008.
39. W. G. Davis, J. B. Bowzard, S. D. Sharma et al., “The 3′ untranslated regions of influenza genomic sequences are 5′PPP-independent ligands for RIG-I,” PLoS One, vol. 7, no. 3, article e32661, 2012.
40. M. Schlee, “Master sensors of pathogenic RNA—RIG-I like receptors,” Immunobiology, vol. 218, no. 11, pp. 1322–1335, 2013.
41. L. Zinzula and E. Tramontano, “Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit,” Antiviral Research, vol. 100, no. 3, pp. 615–635, 2013.
42. C. Lässig, S. Matheisl, K. M. J. Sparrer et al., “Correction: ATP hydrolysis by the viral RNA sensor RIG-I prevents unintentional recognition of self-RNA,” eLife, vol. 5, 2016.
43. D. Luo, A. Kohlway, A. Vela, and A. M. Pyle, “Visualizing the determinants of viral RNA recognition by innate immune sensor RIG-I,” Structure, vol. 20, no. 11, pp. 1983–1988, 2012.
44. D. C. Rawling, M. E. Fitzgerald, and A. M. Pyle, “Establishing the role of ATP for the function of the RIG-I innate immune sensor,” eLife, vol. 4, 2015.
45. M. C. Boelens, T. J. Wu, B. Y. Nabet et al., “Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways,” Cell, vol. 159, no. 3, pp. 499–513, 2014.
46. C. Lassig and K. P. Hopfner, “Discrimination of cytosolic self and non-self RNA by RIG-I-like receptors,” The Journal of Biological Chemistry, vol. 292, no. 22, pp. 9000–9009, 2017.
47. M. A. Jang, E. K. Kim, H. Now et al., “Mutations in DDX58, which encodes RIG-I, cause atypical Singleton-Merten syndrome,” The American Journal of Human Genetics, vol. 96, no. 2, pp. 266–274, 2015.
48. H. Oda, K. Nakagawa, J. Abe et al., “Aicardi-Goutières syndrome is caused by IFIH1 mutations,” The American Journal of Human Genetics, vol. 95, no. 1, pp. 121–125, 2014.
49. G. I. Rice, Y. Del Toro Duany, E. M. Jenkinson et al., “Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling,” Nature Genetics, vol. 46, no. 5, pp. 503–509, 2014.
50. F. Rutsch, M. MacDougall, C. Lu et al., “A specific IFIH1 gain-of-function mutation causes Singleton-Merten syndrome,” The American Journal of Human Genetics, vol. 96, no. 2, pp. 275–282, 2015.
51. S. Rothenfusser, N. Goutagny, G. DiPerna et al., “The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I,” The Journal of Immunology, vol. 175, no. 8, pp. 5260–5268, 2005.
52. A. Komuro and C. M. Horvath, “RNA- and virus-independent inhibition of antiviral signaling by RNA helicase LGP2,” Journal of Virology, vol. 80, no. 24, pp. 12332–12342, 2006.
53. A. Murali, X. Li, C. T. Ranjith-Kumar et al., “Structure and function of LGP2, a DEX(D/H) helicase that regulates the innate immunity response,” Journal of Biological Chemistry, vol. 283, no. 23, pp. 15825–15833, 2008.
54. S. Soonthornvacharin, A. Rodriguez-Frandsen, Y. Zhou et al., “Systems-based analysis of RIG-I-dependent signalling identifies KHSRP as an inhibitor of RIG-I receptor activation,” Nature Microbiology, vol. 2, article 17022, 2017.
55. A. M. Bruns, G. P. Leser, R. A. Lamb, and C. M. Horvath, “The innate immune sensor LGP2 activates antiviral signaling by regulating MDA5-RNA interaction and filament assembly,” Molecular Cell, vol. 55, no. 5, pp. 771–781, 2014.
56. A. M. Bruns, D. Pollpeter, N. Hadizadeh, S. Myong, J. F. Marko, and C. M. Horvath, “ATP hydrolysis enhances RNA recognition and antiviral signal transduction by the innate immune sensor, Laboratory of Genetics and Physiology 2 (LGP2),” Journal of Biological Chemistry, vol. 288, no. 2, pp. 938–946, 2013.
57. M. Si-Tahar, F. Blanc, L. Furio et al., “Protective role of LGP2 in influenza virus pathogenesis,” The Journal of Infectious Diseases, vol. 210, no. 2, pp. 214–223, 2014.
58. A. G. van der Veen, P. V. Maillard, J. M. Schmidt et al., “The RIG-I-like receptor LGP2 inhibits Dicer-dependent processing of long double-stranded RNA and blocks RNA interference in mammalian cells,” The EMBO Journal, vol. 37, no. 4, article e97479, 2018.
59. B. R. tenOever, “Questioning antiviral RNAi in mammals,” Nature Microbiology, vol. 2, no. 5, article 17052, 2017.
60. A. Fullam and M. Schröder, “DExD/H-box RNA helicases as mediators of anti-viral innate immunity and essential host factors for viral replication,” Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, vol. 1829, no. 8, pp. 854–865, 2013.
61. H. Oshiumi, T. Kouwaki, and T. Seya, “Accessory factors of cytoplasmic viral RNA sensors required for antiviral innate immune response,” Frontiers in Immunology, vol. 7, 2016.
62. S. C. Eckard, G. I. Rice, A. Fabre et al., “The SKIV2L RNA exosome limits activation of the RIG-I-like receptors,” Nature Immunology, vol. 15, no. 9, pp. 839–845, 2014.
63. M. Miyashita, H. Oshiumi, M. Matsumoto, and T. Seya, “DDX60, a DEXD/H box helicase, is a novel antiviral factor promoting RIG-I-like receptor-mediated signaling,” Molecular and Cellular Biology, vol. 31, no. 18, pp. 3802–3819, 2011.
64. H. Oshiumi, M. Miyashita, M. Okamoto et al., “DDX60 is involved in RIG-I-dependent and independent antiviral responses, and its function is attenuated by virus-induced EGFR activation,” Cell Reports, vol. 11, no. 8, pp. 1193–1207, 2015.
65. N. Tremblay, M. Baril, L. Chatel-Chaix et al., “Spliceosome SNRNP200 promotes viral RNA sensing and IRF3 activation of antiviral response,” PLoS Pathogens, vol. 12, no. 7, article e1005772, 2016.
66. R. Bordonne, J. Banroques, J. Abelson, and C. Guthrie, “Domains of yeast U4 spliceosomal RNA required for PRP4 protein binding, snRNP-snRNP interactions, and pre-mRNA splicing in vivo,” Genes & Development, vol. 4, no. 7, pp. 1185–1196, 1990.
67. J. Lin and J. J. Rossi, “Identification and characterization of yeast mutants that overcome an experimentally introduced block to splicing at the 3′ splice site,” RNA, vol. 2, no. 8, pp. 835–848, 1996.
68. D. Xu, S. Nouraini, D. Field, S.-J. Tang, and J. D. Friesen, “An RNA-dependent ATPase associated with U2/U6 snRNAs in pre-mRNA splicing,” Nature, vol. 381, no. 6584, pp. 709–713, 1996.
69. P. Fabrizio, B. Laggerbauer, J. Lauber, W. S. Lane, and R. Lührmann, “An evolutionarily conserved U5 snRNP-specific protein is a GTP-binding factor closely related to the ribosomal translocase EF-2,” The EMBO Journal, vol. 16, no. 13, pp. 4092–4106, 1997.
70. J. P. Staley and C. Guthrie, “Mechanical devices of the spliceosome: motors, clocks, springs, and things,” Cell, vol. 92, no. 3, pp. 315–326, 1998.
71. N. Tremblay, M. Baril, L. Chatel-Chaix et al., “Correction: spliceosome SNRNP200 promotes viral RNA sensing and IRF3 activation of antiviral response,” PLoS Pathogens, vol. 13, no. 1, article e1006174, 2017.
72. P. Linder and E. Jankowsky, “From unwinding to clamping — the DEAD box RNA helicase family,” Nature Reviews Molecular Cell Biology, vol. 12, no. 8, pp. 505–516, 2011.
73. T. Kawasaki and T. Kawai, “Toll-like receptor signaling pathways,” Frontiers in Immunology, vol. 5, 2014.
74. S. Jensen and A. R. Thomsen, “Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion,” Journal of Virology, vol. 86, no. 6, pp. 2900–2910, 2012.
75. K. A. Zarember and P. J. Godowski, “Tissue expression of human toll-like receptors and differential regulation of toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines,” Journal of Immunology, vol. 168, no. 2, pp. 554–561, 2002.
76. M. Tatematsu, F. Nishikawa, T. Seya, and M. Matsumoto, “Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA,” Nature Communications, vol. 4, p. 1833, 2013.
77. N. H. Chen, P. P. Xia, S. J. Li, T. J. Zhang, T. T. Wang, and J. Z. Zhu, “RNA sensors of the innate immune system and their detection of pathogens,” IUBMB Life, vol. 69, no. 5, pp. 297–304, 2017.
78. Y. Wang, L. Liu, D. R. Davies, and D. M. Segal, “Dimerization of Toll-like receptor 3 (TLR3) is required for ligand binding,” Journal of Biological Chemistry, vol. 285, no. 47, pp. 36836–36841, 2010.
79. J. Mahita and R. Sowdhamini, “Integrative modelling of TIR domain-containing adaptor molecule inducing interferon-β (TRIF) provides insights into its autoinhibited state,” Biology Direct, vol. 12, no. 1, p. 9, 2017.
80. H. D. Huh, E. Lee, J. Shin, B. Park, and S. Lee, “STRAP positively regulates TLR3-triggered signaling pathway,” Cellular Immunology, vol. 318, pp. 55–60, 2017.
81. W. W. Huai, H. Song, Z. X. Yu et al., “Mint3 potentiates TLR3/4- and RIG-I-induced IFN-β expression and antiviral immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 42, pp. 11925–11930, 2016.
82. J. A. Tomalka, T. J. de Jesus, and P. Ramakrishnan, “Sam68 is a regulator of Toll-like receptor signaling,” Cellular & Molecular Immunology, vol. 14, no. 1, pp. 107–117, 2017.
83. S. Y. Tsai, J. A. Segovia, T. H. Chang et al., “Regulation of TLR3 activation by S100A9,” Journal of Immunology, vol. 195, no. 9, pp. 4426–4437, 2015.
84. E. Borysiewicz, D. Fil, and G. W. Konat, “Rho proteins are negative regulators of TLR2, TLR3, and TLR4 signaling in astrocytes,” Journal of Neuroscience Research, vol. 87, no. 7, pp. 1565–1572, 2009.
85. X. Liu, W. Chen, Q. Wang, L. Li, and C. Wang, “Negative regulation of TLR inflammatory signaling by the SUMO-deconjugating enzyme SENP6,” PLoS Pathogens, vol. 9, no. 6, article e1003480, 2013.
86. X. M. Hu, J. Q. Ye, A. J. Qin, H. T. Zou, H. X. Shao, and K. Qian, “Both microRNA-155 and virus-encoded MiR-155 ortholog regulate TLR3 expression,” PLoS One, vol. 10, no. 5, article e0126012, 2015.
87. P. Kar, D. Kumar, P. K. Gumma, S. J. Chowdhury, and V. K. Karra, “Down regulation of TRIF, TLR3, and MAVS in HCV infected liver correlates with the outcome of infection,” Journal of Medical Virology, vol. 89, no. 12, pp. 2165–2172, 2017.
88. M. R. Al-Anazi, S. Matou-Nasri, A. A. Abdo et al., “Association of Toll-like receptor 3 single-nucleotide polymorphisms and hepatitis C virus infection,” Journal of Immunology Research, vol. 2017, Article ID 1590653, 11 pages, 2017.
89. F. G. Lafaille, I. M. Pessach, S. Y. Zhang et al., “Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells,” Nature, vol. 491, no. 7426, pp. 769–773, 2012.
90. Y. Q. Guo, M. Audry, M. Ciancanelli et al., “Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity,” Journal of Experimental Medicine, vol. 208, no. 10, pp. 2083–2098, 2011.
91. L. Abel, S. Plancoulaine, E. Jouanguy et al., “Age-dependent Mendelian predisposition to herpes simplex virus type 1 encephalitis in childhood,” The Journal of Pediatrics, vol. 157, no. 4, pp. 623–629.e1, 2010.
92. S. Y. Zhang, E. Jouanguy, S. Ugolini et al., “TLR3 deficiency in patients with herpes simplex encephalitis,” Science, vol. 317, no. 5844, pp. 1522–1527, 2007.
93. M. Sironi, A. M. Peri, R. Cagliani et al., “TLR3 mutations in adult patients with herpes simplex virus and varicella-zoster virus encephalitis,” The Journal of Infectious Diseases, vol. 215, no. 9, pp. 1430–1434, 2017.
94. N. Mork, E. Kofod-Olsen, K. B. Sorensen et al., “Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis,” Genes & Immunity, vol. 16, no. 8, pp. 552–566, 2015.
95. P. X. Song, N. Zheng, L. Zhang et al., “Downregulation of interferon-β and Inhibition of TLR3 expression are associated with fatal outcome of severe fever with thrombocytopenia syndrome,” Scientific Reports, vol. 7, no. 1, p. 6532, 2017.
96. P. L. Geng, L. X. Song, H. J. An, J. Y. Huang, S. Li, and X. T. Zeng, “Toll-like receptor 3 is associated with the risk of HCV infection and HBV-related diseases,” Medicine, vol. 95, no. 21, article e2302, 2016.
97. D. Liu, Q. Chen, H. Zhu et al., “Association of respiratory syncytial virus toll-like receptor 3-mediated immune response with COPD exacerbation frequency,” Inflammation, vol. 41, no. 2, 2017.
98. R. Sesti-Costa, M. C. S. Francozo, G. K. Silva, J. L. Proenca-Modena, and J. S. Silva, “TLR3 is required for survival following Coxsackievirus B3 infection by driving T lymphocyte activation and polarization: the role of dendritic cells,” PLoS One, vol. 12, no. 10, article e0185819, 2017.
99. H. F. He, S. H. Liu, P. P. Liu et al., “Association of Toll-like receptor 3 gene polymorphism with the severity of enterovirus 71 infection in Chinese children,” Archives of Virology, vol. 162, no. 6, pp. 1717–1723, 2017.
100. D. Alvarez-Carbonell, Y. Garcia-Mesa, S. Milne et al., “Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells,” Retrovirology, vol. 14, no. 1, p. 9, 2017.
101. S. Cardinaud, A. Urrutia, A. Rouers et al., “Triggering of TLR-3, -4, NOD2, and DC-SIGN reduces viral replication and increases T-cell activation capacity of HIV-infected human dendritic cells,” European Journal of Immunology, vol. 47, no. 5, pp. 818–829, 2017.
102. J. K. Dowling and A. Mansell, “Toll-like receptors: the Swiss army knife of immunity and vaccine development,” Clinical & Translational Immunology, vol. 5, no. 5, article e85, 2016.
103. E. Bardel, R. Doucet-Ladeveze, C. Mathieu, A. M. Harandi, B. Dubois, and D. Kaiserlian, “Intradermal immunisation using the TLR3-ligand poly (I: C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection,” Npj Vaccines, vol. 1, no. 1, article 16010, 2016.
104. E. Poteet, P. Lewis, C. Y. Chen et al., “Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV,” Vaccine, vol. 34, no. 48, pp. 5886–5894, 2016.
105. J. L. Cervantes, B. Weinerman, C. Basole, and J. C. Salazar, “TLR8: the forgotten relative revindicated,” Cellular & Molecular Immunology, vol. 9, no. 6, pp. 434–438, 2012.
106. + T cells,” Nature Immunology, vol. 16, no. 1, pp. 118–128, 2015.
107. J. Dai, B. Liu, and Z. H. Li, “Regulatory T cells and Toll-like receptors: what is the missing link?,” International Immunopharmacology, vol. 9, no. 5, pp. 528–533, 2009.
108. H. Sandig and S. Bulfone-Paus, “TLR signaling in mast cells: common and unique features,” Frontiers in Immunology, vol. 3, 2012.
109. N. Fitzner, S. Clauberg, F. Essmann, J. Liebmann, and V. Kolb-Bachofen, “Human skin endothelial cells can express all 10 TLR genes and respond to respective ligands,” Clinical and Vaccine Immunology, vol. 15, no. 1, pp. 138–146, 2008.
110. K. Rosenberger, K. Derkow, P. Dembny, C. Kruger, E. Schott, and S. Lehnardt, “The impact of single and pairwise Toll-like receptor activation on neuroinflammation and neurodegeneration,” Journal of Neuroinflammation, vol. 11, no. 1, p. 166, 2014.
111. M. T. Abreu, “Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function,” Nature Reviews Immunology, vol. 10, no. 2, pp. 131–144, 2010.
112. M. Awais, K. Wang, X. W. Lin et al., “TLR7 deficiency leads to TLR8 compensative regulation of immune response against JEV in mice,” Frontiers in Immunology, vol. 8, 2017.
113. F. Heil, H. Hemmi, H. Hochrein et al., “Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8,” Science, vol. 303, no. 5663, pp. 1526–1529, 2004.
114. S. S. Diebold, T. Kaisho, H. Hemmi, S. Akira, and C. R. Sousa, “Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA,” Science, vol. 303, no. 5663, pp. 1529–1531, 2004.
115. Y. W. Zhang, M. El-Far, F. P. Dupuy et al., “HCV RNA activates APCs via TLR7/TLR8 while virus selectively stimulates macrophages without inducing antiviral responses,” Scientific Reports, vol. 6, no. 1, 2016.
116. S. T. Sarvestani, M. D. Tate, J. M. Moffat et al., “Inosine-mediated modulation of RNA sensing by Toll-like receptor 7 (TLR7) and TLR8,” Journal of Virology, vol. 88, no. 2, pp. 799–810, 2013.
117. F. C. F. Schmitt, I. Freund, M. A. Weigand, M. Helm, A. H. Dalpke, and T. Eigenbrod, “Identification of an optimized 2′-O-methylated trinucleotide RNA motif inhibiting Toll-like receptors 7 and 8,” RNA, vol. 23, no. 9, pp. 1344–1351, 2017.
118. S. Jung, T. von Thulen, V. Laukemper et al., “A single naturally occurring 2′-O-methylation converts a TLR7- and TLR8-activating RNA into a TLR8-specific ligand,” PLoS One, vol. 10, no. 3, article e0120498, 2015.
119. A. Forsbach, J. G. Nemorin, K. Volp et al., “Characterization of conserved viral leader RNA sequences that stimulate innate immunity through TLRs,” Oligonucleotides, vol. 17, no. 4, pp. 405–418, 2007.
120. T. Querec, S. Bennouna, S. K. Alkan et al., “Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity,” Journal of Experimental Medicine, vol. 203, no. 2, pp. 413–424, 2006.
121. K. Triantafilou, E. Vakakis, E. A. J. Richer, G. L. Evans, J. P. Villiers, and M. Triantafilou, “Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response,” Virulence, vol. 2, no. 1, pp. 22–29, 2014.
122. R. Hamel, O. Dejarnac, S. Wichit et al., “Biology of Zika virus infection in human skin cells,” Journal of Virology, vol. 89, no. 17, pp. 8880–8896, 2015.
123. A. J. Rolfe, D. B. Bosco, J. Y. Wang, R. S. Nowakowski, J. Q. Fan, and Y. Ren, “Bioinformatic analysis reveals the expression of unique transcriptomic signatures in Zika virus infected human neural stem cells,” Cell & Bioscience, vol. 6, no. 1, p. 42, 2016.
124. R. Colisson, L. Barblu, C. Gras et al., “Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells,” Blood, vol. 115, no. 11, pp. 2177–2185, 2010.
125. H. D. Clifford, S. T. Yerkovich, S. K. Khoo et al., “Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccine,” Immunogenetics, vol. 64, no. 3, pp. 219–228, 2012.
126. L. A. J. O’Neill and A. G. Bowie, “The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling,” Nature Reviews Immunology, vol. 7, no. 5, pp. 353–364, 2007.
127. D. Werling, O. C. Jann, V. Offord, E. J. Glass, and T. J. Coffey, “Variation matters: TLR structure and species-specific pathogen recognition,” Trends in Immunology, vol. 30, no. 3, pp. 124–130, 2009.
128. U. Ohto, “Conservation and divergence of ligand recognition and signal transduction mechanisms in Toll-like receptors,” Chemical and Pharmaceutical Bulletin, vol. 65, no. 8, pp. 697–705, 2017.
129. U. Ohto, H. Tanji, and T. Shimizu, “Structure and function of toll-like receptor 8,” Microbes and Infection, vol. 16, no. 4, pp. 273–282, 2014.
130. Z. K. Zhang, U. Ohto, T. Shibata et al., “Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guano-sine and single-stranded RNA,” Immunity, vol. 45, no. 4, pp. 737–748, 2016.
131. H. Tanji, U. Ohto, T. Shibata et al., “Toll-like receptor 8 senses degradation products of single-stranded RNA,” Nature Structural & Molecular Biology, vol. 22, no. 2, pp. 109–115, 2015.
132. J. Q. Wang, Y. S. Jeelall, L. L. Ferguson, and K. Horikawa, “Toll-like receptors and cancer: MYD88 mutation and inflammation,” Frontiers in Immunology, vol. 5, 2014.
133. H. Itoh, M. Tatematsu, A. Watanabe et al., “UNC93B1 physically associates with human TLR8 and regulates TLR8-mediated signaling,” PLoS One, vol. 6, no. 12, article e28500, 2011.
134. C. Y. Chiang, A. Engel, A. M. Opaluch et al., “Cofactors required for TLR7-and TLR9-dependent innate immune responses,” Cell Host & Microbe, vol. 11, no. 3, pp. 306–318, 2012.
135. C. Zannetti, F. Bonnay, F. Takeshita et al., “C/EBPδ and STAT-1 are required for TLR8 transcriptional activity,” Journal of Biological Chemistry, vol. 285, no. 45, pp. 34773–34780, 2010.
136. Z. G. Ramirez-Ortiz, A. Prasad, J. W. Griffith et al., “The receptor TREML4 amplifies TLR7-mediated signaling during antiviral responses and autoimmunity,” Nature Immunology, vol. 16, no. 5, pp. 495–504, 2015.
137. B. Aouar, D. Kovarova, S. Letard et al., “Dual role of the tyrosine kinase Syk in regulation of Toll-like receptor signaling in plasmacytoid dendritic cells,” PLoS One, vol. 11, no. 6, article e0156063, 2016.
138. Y. M. Wang, S. S. Yan, B. Yang et al., “TRIM35 negatively regulates TLR7- and TLR9-mediated type I interferon production by targeting IRF7,” FEBS Letters, vol. 589, no. 12, pp. 1322–1330, 2015.
139. S. Pelletier, N. Bedard, E. Said, P. Ancuta, J. Bruneau, and N. H. Shoukry, “Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C,” Journal of Virology, vol. 87, no. 12, pp. 6769–6781, 2013.
140. F. Z. Fakhir, M. Lkhider, W. Badre et al., “Genetic variations in toll-like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression,” Liver International, vol. 38, no. 3, pp. 432–442, 2018.
141. C. W. Yang and S. M. Chen, “A comparative study of human TLR 7/8 stimulatory trimer compositions in influenza A viral genomes,” PLoS One, vol. 7, no. 2, article e30751, 2012.
142. E. A. Said, F. Al-Yafei, F. Zadjali et al., “Association of single-nucleotide polymorphisms in TLR7 (Gln11Leu) and TLR9 (1635A/G) with a higher CD4T cell count during HIV infection,” Immunology Letters, vol. 160, no. 1, pp. 58–64, 2014.
143. T. A. Abdel-Raouf, A. Ahmed, W. K. Zaki, H. M. Abdella, and M. A. Zid, “Study of toll-like receptor 7 expression and interferon α in Egyptian patients with chronic hepatitis C infection and hepatocellular carcinoma,” Egyptian Journal of Medical Human Genetics, vol. 15, no. 4, pp. 387–392, 2014.
144. C. H. Wang, H. L. Eng, K. H. Lin et al., “TLR7 and TLR8 gene variations and susceptibility to hepatitis C virus infection,” PLoS One, vol. 6, no. 10, article e26235, 2011.
145. F. Li, X. Li, G. Z. Zou, Y. F. Gao, and J. Ye, “Association between TLR7 copy number variations and hepatitis B virus infection outcome in Chinese,” World Journal of Gastroenterology, vol. 23, no. 9, pp. 1602–1607, 2017.
146. L. Trautmann, E. A. Said, R. Halwani et al., “Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections,” Current Opinion in HIV and AIDS, vol. 2, no. 3, pp. 219–227, 2007.
147. S. I. Gringhuis, M. van der Vlist, L. M. van den Berg, J. den Dunnen, M. Litjens, and T. B. H. Geijtenbeek, “HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells,” Nature Immunology, vol. 11, no. 5, pp. 419–426, 2010.
148. E. Khatamzas, M. M. Hipp, D. Gaughan et al., “Snapin promotes HIV-1 transmission from dendritic cells by dampening TLR8 signaling,” EMBO Journal, vol. 36, no. 20, pp. 2998–3011, 2017.
149. R. A. Bam, D. Hansen, A. Irrinki et al., “TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human peripheral blood mononuclear cells,” Antimicrobial Agents and Chemotherapy, vol. 61, no. 1, pp. e01369–e01316, 2016.
150. + T cells indirectly via TNF-α,” The Journal of Immunology, vol. 186, no. 7, pp. 4314–4324, 2011.
151. N. Van Hoeven, C. B. Fox, B. Granger et al., “A formulated TLR7/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines,” Scientific Reports, vol. 7, article 46426, 2017.
152. S. T. Zhang, Z. Hu, H. Tanji et al., “Small-molecule inhibition of TLR8 through stabilization of its resting state,” Nature Chemical Biology, vol. 14, no. 1, pp. 58–64, 2018.
153. N. I. Maria, E. C. Steenwijk, A. S. IJpma et al., “Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren’s syndrome,” Annals of the Rheumatic Diseases, vol. 76, no. 4, pp. 721–730, 2017.
154. W. X. Wu, W. Zhang, E. S. Duggan, J. L. Booth, M. H. Zou, and J. P. Metcalf, “RIG-I and TLR3 are both required for maximum interferon induction by influenza virus in human lung alveolar epithelial cells,” Virology, vol. 482, pp. 181–188, 2015.
155. N. I. Maria, C. G. van Helden-Meeuwsen, E. C. Steenwijk et al., “Nucleic acid sensing receptors TLR7, RIG-I and MDA5 collaborate in driving the systemic IFN signature and amplify the pathogenic loop: potential new targets for therapy in primary Sjogrens syndrome,” Arthritis & Rhematology, vol. 66, pp. S1302–S1302, 2014.
156. L. Slater, N. W. Bartlett, J. J. Haas et al., “Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium,” PLoS Pathogens, vol. 6, no. 11, article e1001178, 2010.